Glypican-1 targeted nanoplatform for pancreatic ductal adenocarcinoma: interpreting findings
Arman Abroumand Gholami, Djalolidin Mansurov, Tolib Bekmirov · 2026
Read Glypican-1 targeted nanoplatform for pancreatic ductal adenocarcinoma: interpreting findings by Arman Abroumand Gholami, Djalolidin Mansurov, Tolib Bekmirov (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13264638.txt.
Description
Arman Abroumand Gholami, Djalolidin Mansurov, and Tolib Bekmirov wrote a 2026 letter to the editor about a nanoparticle therapy for pancreatic cancer. The therapy targets a surface protein called GPC1 and pairs chemo with sound-based treatment and live ultrasound imaging. The letter praises the design but raises three concerns before the work can count as a viable clinical strategy.
First, the study compared its system with a single drug that is not standard care for this cancer, so beating it proves little. Accepted first-line care pairs other drug combinations instead. Second, the mouse model used grows tumors under the skin and lacks the dense, poorly supplied tissue of real pancreatic tumors. That gap weakens claims that targeting drives tumor uptake. The authors urge care in reading the findings.
Catalog record
| CREATOR | Arman Abroumand Gholami, Djalolidin Mansurov, Tolib Bekmirov |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 6267 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |